Bay Area Biotech Investor

Why Endocyte's Small Molecule Drug Conjugates + Imaging Platform Is Undervalued

Endocyte (NASDAQ:ECYT) is a small-cap biopharmaceutical company valued at $457 million with 71 employees located in West Lafayette, Indiana. The company specializes in small molecule drug conjugates (SMDC) with companion imaging diagnostics to target cancer cells ONLY in patients likely to benefit. You can read more about company from its website.

Unique Small Molecule Drug Conjugates (SMDC) + Imaging PlatformEndocyte's lead SMDC is called vintafolide (EC145), which consists of a targeting ligand, folate (or folic acid, an important vitamin nutrient for cell division), a linker/spacer region, and a drug payload, the microtubule destabilizing agent (which causes cell death, apoptosis) called desacetylvinblastine monohydrazide (DAVLBH). Vintafolide selectively binds to the folate receptor (FR) overexpressed on cancer cells, is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details